OBJECTIVE: To evaluate changes in survival among HIV-positive individuals with known date of seroconversion (SC). DESIGN: Prospective cohort study. METHODS: Follow-up lasted from SC to death or to the end of 1997. A multivariate Cox model was applied to estimate relative hazards (RH) of death. The year of SC (as a categoric fixed variable) and calendar year (as a time-dependent variable) were considered to evaluate, respectively, cohort and prevalent changes in the rate of death. A separate Cox model was used to assess the association between survival and new combination therapies, using an "intention to treat" approach. RESULTS: The study included 1535 individuals (53.9% injecting drug users, 25.3% homosexuals, 19.5% heterosexuals); 75.8% seroconverted between 1980 and 1991, and 24.2% seroconverted between 1992 and 1997. When adjusting for year of SC, the RH of death (and that of AIDS) was significantly lower in 1997, compared with before 1991 (RH = 0.54; 95% confidence interval, 0.30-0.98). Adjusted RHs of death were significantly lower for combination antiretroviral therapy, compared with no therapy. When combining the two Cox models, the 1997 reduction in risk of death was largely due to antiretroviral therapies; similar results were obtained when the endpoint was AIDS. CONCLUSIONS: A reduction in the risk of death, probably due to combination antiretroviral therapy, was observed in 1997 after having adjusted for age at SC and year of SC.
OBJECTIVE: To evaluate changes in survival among HIV-positive individuals with known date of seroconversion (SC). DESIGN: Prospective cohort study. METHODS: Follow-up lasted from SC to death or to the end of 1997. A multivariate Cox model was applied to estimate relative hazards (RH) of death. The year of SC (as a categoric fixed variable) and calendar year (as a time-dependent variable) were considered to evaluate, respectively, cohort and prevalent changes in the rate of death. A separate Cox model was used to assess the association between survival and new combination therapies, using an "intention to treat" approach. RESULTS: The study included 1535 individuals (53.9% injecting drug users, 25.3% homosexuals, 19.5% heterosexuals); 75.8% seroconverted between 1980 and 1991, and 24.2% seroconverted between 1992 and 1997. When adjusting for year of SC, the RH of death (and that of AIDS) was significantly lower in 1997, compared with before 1991 (RH = 0.54; 95% confidence interval, 0.30-0.98). Adjusted RHs of death were significantly lower for combination antiretroviral therapy, compared with no therapy. When combining the two Cox models, the 1997 reduction in risk of death was largely due to antiretroviral therapies; similar results were obtained when the endpoint was AIDS. CONCLUSIONS: A reduction in the risk of death, probably due to combination antiretroviral therapy, was observed in 1997 after having adjusted for age at SC and year of SC.
Authors: Liselotte van Asten; Robert Zangerle; Ildefonso Hernández Aguado; Faroudy Boufassa; Barbara Broers; Raymond P Brettle; J Roy Robertson; Jim McMenamin; Roel A Coutinho; Maria Prins Journal: Eur J Epidemiol Date: 2005 Impact factor: 8.082
Authors: Manuela García de la Hera; Inmaculada Ferreros; Julia del Amo; Patricia García de Olalla; Santiago Pérez Hoyos; Roberto Muga; Jorge del Romero; Rafael Guerrero; Ildefonso Hernández-Aguado Journal: J Epidemiol Community Health Date: 2004-11 Impact factor: 3.710
Authors: Meredith S Shiels; Stephen R Cole; Joan S Chmiel; Joseph Margolick; Jeremy Martinson; Zuo-Feng Zhang; Lisa P Jacobson Journal: J Clin Epidemiol Date: 2009-10-31 Impact factor: 6.437
Authors: Meredith S Shiels; Stephen R Cole; Scott Wegner; Haroutune Armenian; Joan S Chmiel; Anuradha Ganesan; Vincent C Marconi; Otoniel Martinez-Maza; Jeremy Martinson; Amy Weintrob; Lisa P Jacobson; Nancy F Crum-Cianflone Journal: J Acquir Immune Defic Syndr Date: 2008-08-01 Impact factor: 3.731
Authors: Lauren E Cain; Stephen R Cole; Sander Greenland; Todd T Brown; Joan S Chmiel; Lawrence Kingsley; Roger Detels Journal: Am J Epidemiol Date: 2009-03-24 Impact factor: 4.897
Authors: J del Amo; J del Romero; A Barrasa; S Pérez-Hoyos; C Rodríguez; M Díez; S García; V Soriano; J Castilla Journal: Sex Transm Infect Date: 2002-08 Impact factor: 3.519
Authors: Abdel Babiker; Janet Darbyshire; Patrizio Pezzotti; Kholoud Porter; Giovanni Rezza; Sarah A Walker; Valerie Beral; Roel Coutinho; Julia Del Amo; Noël Gill; Christine Lee; Laurence Meyer; Freya Tyrer; Francois Dabis; Rodolphe Thiebaut; Sylvie Lawson-Aye; Faroudy Boufassa; Osamah Hamouda; Klaus Fischer; Patrizio Pezzotti; Giovanni Rezza; Giota Touloumi; Angelos Hatzakis; Anastasia Karafoulidou; Olga Katsarou; Ray Brettle; Jorge del Romero; Maria Prins; Birgit van Benthem; Ole Kirk; Court Pederson; Idelfonso Hernández Aguado; Santiago Pérez-Hoyos; Anne Eskild; Johan N Bruun; Mette Sannes; Caroline Sabin; Christine Lee; Anne M Johnson; Andrew N Phillips; Patrick Francioli; Philippe Vanhems; Mathias Egger; Martin Rickenbach; David Cooper; John Kaldor; Lesley Ashton; Jeanette Vizzard; Roberto Muga; Nicholas E Day; Daniela De Angelis Journal: Int J Epidemiol Date: 2002-10 Impact factor: 7.196